{'fraction_non_alphanumeric': 0.05128205128205128, 'fraction_numerical': 0.0310391363022942, 'mean_word_length': 5.235294117647059, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Urinary markers for prostate cancer.

Immunoglobulins (Igs), bombesin-like immunoreactivity (BLI), beta-2 microglobulin (beta-2m) and transferrin were measured by radioimmunoassay in the first voided urine of patients with advanced prostatic carcinoma. Compared to 16 age-matched, healthy subjects, urinary Igs were elevated in 19 (48%), BLI in 12 (30%), beta-2m in 29 (74%) and transferrin in 8 (20%) of 40 adenocarcinoma patients. Elevation in urinary Igs, BLI or beta-2m was associated with a significantly shorter survival. The four urine markers correlated well with serum chromogranin A but not with serum prostate-specific antigen. Results suggest that these urine markers are elevated with high frequency in advanced prostate cancer.